University of Minnesota

Max International, LLC

The United States Government as Represented by the Department of Veterans Affairs

Herbert T Nagasawa

Chul-Hoon Kwon

Jonathan F Cohen

Robert Vince

David T Bagley

Carolyn Ann Fairbanks

George Latimer Wilcox

Kelley F Kitto

Steven Earl Patterson

Scott Momii

William B Rathbun

Scott Nagasawa

Jeanette C Roberts

Alexandre Monteil

Cristina D Peterson

The invention provides a compound of formula I and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the formula I compounds, as well as methods of using such as therapeutic agents for the treatment of pain-related disorders and diseases and in combination with other therapeutic agents.

Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

The invention provides compositions and methods for treating cyanide poisoning.

Therapeutic formulations and methods

The present invention relates to compositions and methods for reducing oxidative stress in a cell, increasing glutathione levels in a cell, increasing L-cysteine levels in a cell and reducing hepatocytotoxicity by contacting a cell with a sulfhydryl protected glutathione prodrug or a sulfhydryl protected cysteine prodrug.

Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug

A therapeutic method is provided comprising treating a mammal subject to hypoxia with an amount of 2(R,S)-D-ribo-(1',2&#x2032;,3&#x2032;,4&#x2032;-tetrahydroxybutyl)thiazolidine-4(R)-carboxylic acid (RibCys) or a pharmaceutically acceptable salt thereof effective to both maintain, restore or increase both the ATP levels and the glutathione (GSH) levels in said tissue.

Method to enhance delivery of glutathione and ATP levels in cells

The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products.

Compositions comprising sugar-cysteine products

N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents

A pharmaceutical unit dosage form comprising an amount of a compound of the formula: ##STR1## is provided wherein R.sup.1 is a (C.sub.1 -C.sub.20)alkyl group, a (C.sub.6 -C.sub.12)aryl group, or a C.sub.3 -C.sub.18)cycloalkyl group and R.sup.2 is H or a (C.sub.1 -C.sub.19)alkyl group, a (C.sub.6 -C.sub.12)aryl group, a (C.sub.7 -C.sub.13)arylalkoxy group, a (C.sub.1 -C.sub.6)alkyoxy group, a (C.sub.3 -C.sub.18)cycloalkyl group, a ##STR2## group, or a --CH(R.sup.3)NH.sub.2 group wherein R.sup.3 is a side chain of a natural amino acid, and the pharmaceutically acceptable salts thereof; in combination with a pharmaceutically acceptable carrier, wherein said amount is effective to increase the concentration of glutathione in tissue.

Compounds that enhance the concentration of glutathione in tissues

Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.

Acylated cyanamide compounds

Acylated cyanamide composition

A method comprising stimulating the biosynthesis of glutathione in mammalian cells by contacting the cells with an effective amount of a compound of the formula: ##STR1## wherein R is a (CHOH).sub.n CH.sub.2 OH and wherein n is 1-5, preferably R is derived from a D-aldose monosaccharide.

Growing community of inventors

Irvine, CA, United States of America

Herbert T Nagasawa